Neurocrine Biosciences CEO Kevin Charles Gorman Unloads 108,000 Shares (NBIX)
Neurocrine Biosciences (NASDAQ:NBIX) CEO Kevin Charles Gorman sold 108,000 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $16.76, for a total value of $1,810,080.00. Following the transaction, the chief executive officer now directly owns 177,202 shares of the company’s stock, valued at approximately $2,969,906. The sale was disclosed in a filing with the SEC, which is available at this link.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded down 2.34% on Wednesday, hitting $18.08. 4,215,130 shares of the company’s stock traded hands. Neurocrine Biosciences has a one year low of $8.30 and a one year high of $18.62. The stock has a 50-day moving average of $9.70 and a 200-day moving average of $11.79. The company’s market cap is $1.218 billion.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings data on Tuesday, October 29th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.20) by $0.03. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.79 million. During the same quarter last year, the company posted ($0.05) earnings per share. Neurocrine Biosciences’s revenue was down 92.2% compared to the same quarter last year. On average, analysts predict that Neurocrine Biosciences will post $-0.70 earnings per share for the current fiscal year.
NBIX has been the subject of a number of recent research reports. Analysts at Nomura initiated coverage on shares of Neurocrine Biosciences in a research note to investors on Wednesday. They set a “buy” rating on the stock. Separately, analysts at Morgan Stanley downgraded shares of Neurocrine Biosciences from an “overweight” rating to an “equal weight” rating in a research note to investors on Wednesday. They now have a $16.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Neurocrine Biosciences from $16.00 to $23.00 in a research note to investors on Wednesday. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $18.73.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.